PASSION FOR PRECISION.
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.
ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information please visit: www.itm-radiopharma.com.
Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines
Location: Germany, Bavaria, Garching bei München
Employees: 201-500
Total raised: $322.13M
Founded date: 2004
Funding Rounds 2
Date | Series | Amount | Investors |
06.05.2023 | - | $285.87M | Nextech In... |
28.03.2022 | - | $36.26M | - |
Mentions in press and media 14
Date | Title | Description | Source |
28.12.2023 | These are the 23 largest European funding rounds of 2023 | Read this article in: Over the last two decades, Europe’s startup ecosystem has transformed, evolvi... | siliconcan... |
13.06.2023 | ITM Opens World's Largest Lutetium-177 Production Facility f... | ITM Isotope Technologies Munich SE (ITM) opened its new production facility for Lutetium-177 for tar... | bio-m.org/... |
06.05.2023 | ITM raises record sum of 255 million euros | Garching-based ITM has announced one of the largest private investment rounds in European biotechnol... | bio-m.org/... |
18.08.2022 | ITM Acquires a New Platform for the Development of Next-Gene... | • Technology platform for PET tracers strengthens ITM's radiodiagnostic portfolio • Additional asse... | einpresswi... |
21.06.2022 | ITM: New Isotope Production System at Bruce Power Successful... | First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale... | globenewsw... |
28.03.2022 | ITM Isotope Technologies Munich Receives €33M Equity Funding... | ITM Isotope Technologies Munich SE, a Munich, Germany-based radiopharmaceutical biotech company, clo... | finsmes.co... |
03.02.2022 | ITM Announces Key Appointments to its U.S. Leadership Team | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced t... | marketscre... |
25.01.2022 | ITM Announces First Patient Treated in Second Phase III Tria... | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today annou... | marketscre... |
19.01.2022 | ITM Presents Study Design of COMPOSE Phase III Trial with IT... | ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today annou... | marketscre... |
03.11.2021 | ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. ... | ITM Isotope Technologies Munich SE today announced the presentation of the design of its new phase I... | marketscre... |
Show more